We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Ariadne Technology Licensed by Takeda for Evaluation of Potential Antibody Targets

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ariadne Technology Licensed by Takeda for Evaluation of Potential Antibody Targets"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Ariadne announces that Takeda San Francisco, Takeda's global center for excellence for biologics, has signed an agreement to license Ariadne's Pathway Studio® software. Takeda plans to utilize the software and underlying text-mining algorithms in their discovery program against cancer, inflammatory and metabolic diseases.

"We are pleased to add Takeda to our already distinguished list of clients", says Gabriella Armin, Director of Marketing for Ariadne. "Our solutions for the pharmaceutical discovery pipeline are proven and we believe this research can enable the ongoing development of novel product candidates for therapeutic use."